« Back to Record
Citation APA

Van Praet, C., Filleul, B., Schallier, D., Machiels, J. P., Schrijvers, D., Everaert, E., D'Hondt, L., Werbrouck, P., Vermeij, J., Mebis, J., Clausse, M., Rottey, S., Rasschaert, M., Van Erps, J., Verheezen, J., Van Haverbeke, J., Goeminne, J. C., Lumen, N., Van Hende, F., Pelgrims, G., Demey, W., Van Aelst, F., Wynendaele, W., Gil, T., & Schatteman, P. (2017). Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? Clinical Genitourinary Cancer, 15(4), 502-508. doi:10.1016/j.clgc.2017.01.019


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/256514

Van Praet, C., Filleul, B., Schallier, D., Machiels, J. P., Schrijvers, D., Everaert, E., D'Hondt, L., Werbrouck, P., Vermeij, J., Mebis, J., Clausse, M., Rottey, S., Rasschaert, M., Van Erps, J., Verheezen, J., Van Haverbeke, J., Goeminne, J. C., Lumen, N., Van Hende, F., Pelgrims, G., Demey, W., Van Aelst, F., Wynendaele, W., Gil, T., & Schatteman, P. (2017). Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? Clinical Genitourinary Cancer, 15(4), 502-508. doi:10.1016/j.clgc.2017.01.019